Click to Share
 
 
  1. Latest News
  2. Submit Press Release
  1. PR Home
  2. Latest News
  3. Feeds
  4. Alerts
  5. Submit Free Press Release
  6. Journalist Account
  7. PRNewswire Distribution

napsr Press Releases

  + XML/RSS  



By NAPSRx
Baxter and Halozyme have received approval of their subcutaneous treatment, HYQVIA to treat adult patients with primary immunodeficiency (PI).

By NAPSRx
Takeda Pharmaceuticals and Orexigen® Therapeutics, Inc  have announced the FDA  approval of Contrave®  ®(naltrexone HCI and bupropion HCI) extended release tablets to treat obese or overweight adults  with at least one...

By NAPSRx
Novartis heralds breakthrough clinical results with experimental drug to treat heart failure. ‘It’s been at least a decade since we've had a breakthrough of this magnitude,’’ said Dr. Clyde Yancy, cardiology chief at Northwestern University

By NAPSRx
Mylan is an industry leader in the generics and specialty pharmaceuticals market with sales in approximately 140 countries and territories.

By NAPSRx
According to Thomson Reuters, the pharmaceutical industry’s sales will amount to $1 Trillion in 2014.

By NAPSRx
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) has received FDA approval for Ferric Citrate (formerly known as Zerenex) to control serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.

By NAPSRx
Keytruda, developed by Merck is intended for patients with advanced melanoma and who are unresponsive to other therapies.

By NAPSRx
The new life science division of Google called Calico will join forces with Abbvie to collaborate on the discovery, development and commercialization of new therapies in a research deal worth approximately $1.5 billion.

By NAPSRx
ELELYSO is the first FDA-approved plant cell-based recombinant therapeutic protein and is currently marketed in the United States by Pfizer Inc.

By NAPSRx
Amgen is dedicated to discovering, developing, manufacturing and delivering innovative human therapeutics for patients with debilitating illnesses.

By NAPSRx
The U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for Promacta® developed by GlaxoSmithKline (GSK) to treat a rare bone marrow disorder.

By NAPSRx
Roche looks to expand their respiratory portfolio by acquiring InterMune Inc, a California based biotechnology company and their lead product pirfenidone for idiopathic pulmonary fibrosis (IPF).

By NAPSRx
ViiV Healthcare is a global specialist company established in November 2009 by GlaxoSmithKline (LSE: GSK) and Pfizer (NYSE: PFE) specializing in the treatment and care for people living with HIV.

By NAPSRx
Eliquis, a jointly developed therapy from Pfizer and Bristol-Myers Squibb has been approved by the FDA to treat deep vein thrombosis (DVT), pulmonary embolism (PE), and for the reduction in the risk of recurrent DVT and PE following initial therapy.

By NAPSRx
GlaxoSmithKline (GSK)– a world leader in the healthcare industry specializes in researching and developing vaccines, medicines and consumer healthcare products to improve people’s health and well-being.

By NAPSRx
The investigational antibiotic CAZ-AVI was studied in patients with intra-abdominal infections (cIAI).

By NAPSRx
Based on favorable results obtained from the ADVANCE Phase 3 Study, the FDA approval of PLEGRIDY™ signifies a blockbuster therapeutic achievement for Biogen Idec .

By NAPSRx
Avastin becomes the first biologic medicine to approved in combination with chemotherapy to help women with advanced cervical cancer live longer.

By NAPSRx
Industry leader Sanofi and MannKind Corp have agreed to a enter into a global licensing agreement to develop and market AFREZZA® (Insulin human) rapid- acting inhaled insulin.

By NAPSRx
The collaboration between Daiichi Sankyo and Charleston Labs marks a significant venture for the pain management market.

All Press Releases

By NAPSRx
Baxter and Halozyme have received approval of their subcutaneous treatment, HYQVIA to treat adult patients with primary immunodeficiency (PI).

By NAPSRx
Takeda Pharmaceuticals and Orexigen® Therapeutics, Inc  have announced the FDA  approval of Contrave®  ®(naltrexone HCI and bupropion HCI) extended release tablets to treat obese or overweight adults  with at least one...

By NAPSRx
Novartis heralds breakthrough clinical results with experimental drug to treat heart failure. ‘It’s been at least a decade since we've had a breakthrough of this magnitude,’’ said Dr. Clyde Yancy, cardiology chief at Northwestern University

By NAPSRx
Mylan is an industry leader in the generics and specialty pharmaceuticals market with sales in approximately 140 countries and territories.

By NAPSRx
According to Thomson Reuters, the pharmaceutical industry’s sales will amount to $1 Trillion in 2014.

By NAPSRx
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) has received FDA approval for Ferric Citrate (formerly known as Zerenex) to control serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.

By NAPSRx
Keytruda, developed by Merck is intended for patients with advanced melanoma and who are unresponsive to other therapies.

By NAPSRx
The new life science division of Google called Calico will join forces with Abbvie to collaborate on the discovery, development and commercialization of new therapies in a research deal worth approximately $1.5 billion.

By NAPSRx
Biotech giant Abbvie's collaborative deal with Infinity Pharmaceuticals to develop and market duvelisib is worth approximately $800 million.

By NAPSRx
ELELYSO is the first FDA-approved plant cell-based recombinant therapeutic protein and is currently marketed in the United States by Pfizer Inc.

By NAPSRx
Amgen is dedicated to discovering, developing, manufacturing and delivering innovative human therapeutics for patients with debilitating illnesses.

By NAPSRx
The U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for Promacta® developed by GlaxoSmithKline (GSK) to treat a rare bone marrow disorder.

By NAPSRx
Roche looks to expand their respiratory portfolio by acquiring InterMune Inc, a California based biotechnology company and their lead product pirfenidone for idiopathic pulmonary fibrosis (IPF).

By NAPSRx
ViiV Healthcare is a global specialist company established in November 2009 by GlaxoSmithKline (LSE: GSK) and Pfizer (NYSE: PFE) specializing in the treatment and care for people living with HIV.

By NAPSRx
Eliquis, a jointly developed therapy from Pfizer and Bristol-Myers Squibb has been approved by the FDA to treat deep vein thrombosis (DVT), pulmonary embolism (PE), and for the reduction in the risk of recurrent DVT and PE following initial therapy.

By NAPSRx
GlaxoSmithKline (GSK)– a world leader in the healthcare industry specializes in researching and developing vaccines, medicines and consumer healthcare products to improve people’s health and well-being.

By NAPSRx
Cerdelga™ is the only first-line oral therapy approved to treat adults with Type 1 Gaucher Disease, a rare genetic disorder that affects specific cells and organs in the body.

By NAPSRx
The investigational antibiotic CAZ-AVI was studied in patients with intra-abdominal infections (cIAI).

By NAPSRx
Based on favorable results obtained from the ADVANCE Phase 3 Study, the FDA approval of PLEGRIDY™ signifies a blockbuster therapeutic achievement for Biogen Idec .

By NAPSRx
Avastin becomes the first biologic medicine to approved in combination with chemotherapy to help women with advanced cervical cancer live longer.

By NAPSRx
Industry leader Sanofi and MannKind Corp have agreed to a enter into a global licensing agreement to develop and market AFREZZA® (Insulin human) rapid- acting inhaled insulin.

By NAPSRx
The collaboration between Daiichi Sankyo and Charleston Labs marks a significant venture for the pain management market.

By NAPSRx
Actavis plc (NYSE: ACT) is a specialty pharmaceutical company specializing in developing, manufacturing and commercializing generic drugs and branded pharmaceutical products.

By NAPSRx
Teva is a manufacturer of generics and specialty pharmaceuticals and is currently the world leader in generic drug sales.

By NAPSRx
The approval of Stiverdi Respimat is another great achievement for Boehringer Ingelheim as they continuously expand on their respiratory product pipeline.

By NAPSRx
AstraZeneca’s respiratory franchise is expected to see a significant boost with the assumption of Almirall’s pipeline of novel respiratory assets.

By NAPSRx
Bayer Group had an impressive second quarter for 2014 as earnings climbed based on successful drug launches and the company's established product pipeline.

By NAPSRx
IMBRUVICA®, a jointly developed therapy from Pharmacyclics, Inc. and Janssen Biotech received full Approval based on Phase 3 RESONATE™ study data

By NAPSRx
Abbvie is a global biopharmaceutical specializing in the discovery and advancement of innovative therapies to meet the health needs of people and societies around the globe.

By NAPSRx
Based on industry analysis, the emerging healthcare market will experience a continuous growth in the pharmaceutical sales sector.

By NAPSRx
Cubist Pharmaceuticals, Inc announced on Friday, June 20, 2014 that the U.S. Food and Drug Administration (FDA) approved Sivextro to treat bacterial skin infections.

By NAPSR
Researchers at the University of Illinois at Chicago have developed a system for precisely delivering anti-inflammatory drugs to immune cells gone out of control, while sparing their well-behaved counterparts.

By NAPSR
According to the Centers for Disease Control, more than two million people come down with antibiotic-resistant infections annually, and at least 23,000 die because their treatment can't stop the infection. In addition, the pipeline for new antibiotic

By NAPSR
Artificial bone marrow may be used to reproduce hematopoietic stem cells. A prototype has now been developed by scientists of KIT, the Max Planck Institute for Intelligent Systems, Stuttgart, and Tübingen University (Germany).

By NAPSR
Pfizer Inc. has entered into an agreement with GSK to explore the anti-cancer efficacy and the safety of GSK's trametinib combined with Pfizer's palbociclib (PD-0332991) in a Phase I/II study in patients with advanced/metastatic melanoma.

By NAPSR
A study published in the journal Nature Medicine suggests a potential new treatment for the seizures that often plague children with genetic metabolic disorders and individuals undergoing liver failure.

By NAPSRx
The most frequently mutated gene across all types of cancers is a gene called p53. Unfortunately it has been difficult to directly target this gene with drugs. Now a multi-institutional research team has identified a family of enzymes.

By NAPSR
The Bayer Group continued its positive business momentum in the third quarter of 2013, with substantial contributions from the Life Science businesses HealthCare and CropScience

By NAPSR
A team of 22 scientists from 11 research institutes led by Professor Bazbek Davletov, now at the University of Sheffield, created and characterised a new molecule that was able to alleviate hypersensitivity to inflammatory pain.

By NAPSR
Pfizer Inc. reported financial results for third-quarter 2013. Reported revenues decreased $310 million, or 2%, which reflects an operational decline of $38 million, or less than 1%, and the unfavorable impact of foreign exchange of $272 m

By NAPSR
An international team led by University of Adelaide researchers has identified the mechanism of pain relief of a new drug for treating Irritable Bowel Syndrome with Constipation (IBS-C)

By NAPSR
A new review suggests that omega-3 fatty acids taken in excess could have unintended health consequences in certain situations, and that dietary standards based on the best available evidence need to be established.

By NAPSR
University of Miami Miller School of Medicine researchers played a key role in the largest international Alzheimer's disease genetics collaboration, which identified 11 new regions of the genome that contribute to late-onset Alzheimer's disease.

By NAPSR
Bristol-Myers Squibb Company (NYSE:BMY) has reported results for the third quarter of 2013 highlighted by the strong performance of key marketed products such as Yervoy, Orencia and Sprycel.

By NAPSR
In a feat of modern-day alchemy with huge potential for regenerative medicine, Stanford University School of Medicine scientists have developed a fast, efficient way to turn cells extracted from routine liposuction into liver cells.

By NAPSR
Biotech drugmaker Amgen Inc. said Tuesday that its third-quarter profit jumped 24 percent, trouncing analysts' expectations, as sales of more than a half-dozen of its drugs increased by double digits, one of them helped by a big government purchase.

By NAPSR
The investigational drug AZD9291, a third-generation EGFR inhibitor, showed promise in preclinical studies and provides hope for patients with advanced lung cancers that have become resistant to existing EGFR inhibitors.

By NAPSR
Parvoviruses cause no harm in humans, but they can kill cancer cells. Scientists at the German Cancer Research Center have been studying these viruses with the aim of developing a viral therapy to treat a type of aggressively growing brain cancer.

By NAPSR
Scientists have combined cutting edge computer modelling with pharmacology and medicinal chemistry to reveal new insights into how the body interacts with novel drug treatments.

By NAPSR
Abbott today announced financial results for the third quarter ended Sept. 30, 2013. Third-quarter 2013 worldwide sales of $5.4 billion increased 4.3 percent on an operational basis, with strong performance in Diagnostics and Medical Devices.



Page:

Page updated every 10 minutes


  1. SiteMap
  2. Contact PRLog
  3. Privacy Policy
  4. Terms of Service
  5. Copyright Notice
  6. About
  7. Advertise
Like PRLog?
9K2K1K
Click to Share